Navigation Links
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
Date:11/13/2008

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar(R) (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). Trelstar(R) is a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic prostate cancer. Once approved, Trelstar(R) will be commercialised in the U.S. by Watson Pharmaceuticals, Inc.

"Last September we announced the filing of the product with the European Agencies, under the name Decapeptyl(R). We are proud to have accomplished the simultaneous filings of Trelstar(R) and Decapeptyl(R) in both the U.S. and Europe, it's a great achievement for us," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This demonstrates our ability to work effectively not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, Debio R.P., will produce both products for global distribution."

The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of Trelstar(R), which are already marketed by Watson Pharmaceuticals, Inc.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

Debiopharm S.A. Contacts Additional Media Contacts

In London

Maurice Wagner Maitland

Director Corporate Affairs & Brian Hudspith

Communications Tel: +44 (0)20 7379 5151

Tel.: +41 (0)21 321 01 11 bhudspith@maitland.co.uk

Fax : +41 (0)21 321 01 69

mwagner@debiopharm.com

Jo-Anne Lutjens In New York

Communications Manager Russo Partners, LLC

Tel.: +41 (0)79 370 27 15 Wendy Lau

Fax: +41 (0)21 321 01 69 Tel: +1 212-845-4272

jalutjens@debiopharm.com Fax: +1 212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
2. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
3. In a Down Economy, Womens Health Company Announces Growth
4. R&Q Solutions, LLC Announces Launch to Serve Regions Medical Device Industry
5. WellPoint Announces Second Annual Innovation Event
6. CVS Caremark All Kids Can Announces the Opening of a Boundless Playground in Los Angeles to Serve Children of All Abilities
7. Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform
8. HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences
9. Wound Management Technologies, Inc. Announces FDA Clearance of 510k
10. GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director
11. Governor Rendell Announces the Passing of Lt. Gov. Catherine Baker Knoll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: